Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, HALOZYME THERAPEUTICS, INC. reported revenue of $1.40B, up 37.6% year over year. Operating margin was 33.6% and net margin 22.7%, on a free-cash-flow margin of 46.2% with capital expenditure at 0.5% of revenue. Every figure is computed directly from HALO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.40B | 33.6% | 22.7% |
| FY2024 | $1.02B | 54.3% | 43.7% |
| FY2023 | $829M | 40.7% | 34.0% |
| FY2022 | $660M | 40.5% | 30.6% |
| FY2021 | $443M | 62.2% | 90.8% |
How does HALO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.